Scholars Central

Conference abstractPublished 2 Nov 2017

Novel particulate vaccines for infectious diseases

Authors: Martin J D’Souza

Mercer University, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

We have been working on designing and developing nanovaccines for infectious diseases at the Nanotechnology Laboratory at Mercer University. In particular, we focus on particulate vaccines that offer several advantages over the traditional vaccines, such as superior vaccine stability, the avoidance of cold-chain requirements, and the ease of manufacture. Further, the overall enhanced immune response due to a combination of factors, such as slow release of antigen from the particles and superior uptake into antigen presenting cells of the immune system, makes particulate vaccines the preferred choice of vaccine delivery. The availability of safe bio-degradable and bio-compatible polymers enhances its suitability for human use. Novel delivery of microparticulate vaccines such as transdermal delivery using microneedles and laser ablation, nasal delivery, buccal delivery, and oral delivery of vaccines, amongst others, will also be discussed. Several examples of successful delivery of particulate vaccines in the areas of infectious diseases such as gonorrhea, RSV, influenza, will be discussed.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • SubjectInfectious Diseases
  • SubjectVaccines & Immunisation
  • BylineArticles whose byline prints “Martin J D’Souza”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels